Aim
To prepare guidelines for testing new endocrine agents for therapy of cancer.
2. Introduction 2.1. The current situation The endocrine agents in current use for the treatment of cancer have principally originated from programmes aimed at producing drugs for other indications. Observations of their actions and side-effects in patients subsequently resulted in their use as anti-cancer agents. Their beneficial effects in patients with hormone-sensitive cancers have led to the production of a large number of newer compounds, often developed for patients with cancer. In addition, patients with types of cancer other than the classical steroid-sensitive cancers have been considered as candidates for endocrinerelated therapies.
2.2 The problem Although current guidelines for the conduct of phase I and II trials of cytotoxic agents may cover some problems of endocrine-type therapies, these agents work in radically different ways from cytotoxic drugs and different problems are associated with their development. Thus, the selection procedures are different. The dose needed to achieve a particular maximal effect can often be determined and may be much lower than the maximal tolerated dose (MTD). Unlike cytotoxic agents, most currently available endocrine therapies are best given by continual oral therapy which contrasts markedly to the situation for cytotoxic agents, where doses near the MTD are generally given intermittently and intravenously.
Guidelines for phase I and II clinical trials of cytotoxic drugs in the treatment of cancer have been agreed by the Cancer Research Campaign Phase I/II Clinical Trials Committee, and these have been used to draw up equivalent recommendations for clinical trials with endocrine agents.
We recognise that the requirement of the licensing authority for physicians undertaking a limited trial of a drug in their own patients are less demanding than those required of a pharmaceutical company seeking a clinical trials certificate. For the academic physician, however, the cost of such toxicology would prevent many potentially useful anti-cancer agents being tested. The aim of this document is, therefore, to establish guidelines for the selection, preclinical toxicology, quality control and clinical study of new endocrine agents selected in hospitals and university departments. In all the four sections above, the effect of the drug on the oestrous cycle should also be studied. In the case of hormones linked to cytotoxic molecules, an additional set of requirements must be studied, including reversibility of receptor binding, the alkylating potency in the Epstein NBPtest and comparison of inhibition of the hormoneindependent MDA-MC-or Evsa-T cell lines with a hormone dependent cell line such as MCF-7. Additional anti-tumour activity should be examined in further non-hormone sensitive tumour models (e.g. P388 and the B16-melanoma and colorectal human xenografts). Thus species selection for relevance in man is more difficult than normal. Taking a very broad view on the basis of toxicological experience, the rat is the best predictor of hazard. We would therefore recommend the rat is the species for the single and repeated dose studies. The disadvantage is the larger quantity of new compound required compared with the situation where the mouse would be used. Group sizes should be of six to ten animals. The route of administration should be the anticipated route for man. For orally administered agents, gavage rather than intake with the food should be adopted. Consideration must be given to suitable control groups. This is particularly important where the formulation of the dose may involve suspending agents etc.
A repeated dose study of 3-4 weeks in rats should permit a 1-2 week trial in patients. This would not be long enough to assess a new product adequately but would at least provide ample opportunity of determining the endocrinological changes induced in man by the new agent, any acute symptoms and sites of toxicity, and preliminary data on the simple pharmacokinetics and metabolism of the new compound. The latter aspect should be paralleled by similar studies in the rat. 
Special considerations

Other concurrent therap)
A record of all concurrent non-anti-tumour drugs used should be provided at the end of the study.
13. Flow of information and recolds 13.1. Stud) co-ordinator A co-ordinator will be appointed to collate all studies on a single drug within a group.
Registration
Qualifying patients are registered with the study co-ordinator for assignment of drug dose and starting date. Flow sheets including tumour measurements will be used to record day to day observations on symptoms, signs and laboratory data.
Sunmary sheet
A summary sheet will be prepared by the study co-ordinator.
Sudden toxicity procedure
The study coordinator is called at once in case of pronounced toxicity; he or she will inform the investigators in charge of other patients in the study.
Regulatory requirements
A form for doctors and dentists exemption certificates must be submitted to the DHSS (form MLA 162) (UK only).
